ALFA Filings
Every announcement, straight from the exchange
Every RPG Life Sciences results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements with these filters
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
RPG Life Sciences reported Q1 FY27 Revenue of ₹195.7 Crore, a 15.8% increase, with EBITDA growing 17.9% to ₹48.0 Crore.
RPG Life Sciences reported a 23.6% Y-o-Y revenue increase to ₹176.9 Crore for Q4 FY26, with an EBITDA margin of 25.6%. Full-year FY26 revenue grew 8.3% to ₹707.5 Crore. The Board recommended a 300% dividend (₹24 per share). Growth was driven by robust performance in Domestic Formulations and a strong recovery in the API division.